Sight Sciences (SGHT) Set to Release Quarterly Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is projected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $23.51 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Wednesday, August 5th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.10. The firm had revenue of $23.39 million during the quarter, compared to the consensus estimate of $21.72 million. On average, analysts expect Sight Sciences to post ($0.48) EPS for the current fiscal year and ($0.37) EPS for the next fiscal year.

Sight Sciences Price Performance

SGHT stock traded up $0.30 during mid-day trading on Wednesday, reaching $9.33. The company had a trading volume of 24,236 shares, compared to its average volume of 271,263. Sight Sciences has a 52 week low of $3.38 and a 52 week high of $9.71. The stock has a 50 day simple moving average of $8.52 and a two-hundred day simple moving average of $5.98. The company has a market capitalization of $513.92 million, a price-to-earnings ratio of -16.66 and a beta of 2.45.

Insider Buying and Selling at Sight Sciences

In other Sight Sciences news, CTO David Badawi sold 7,797 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total transaction of $70,562.85. Following the transaction, the chief technology officer directly owned 1,975,075 shares in the company, valued at approximately $17,874,428.75. This represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Rodberg sold 7,208 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $8.85, for a total value of $63,790.80. Following the transaction, the chief financial officer directly owned 216,829 shares in the company, valued at approximately $1,918,936.65. This trade represents a 3.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 47,646 shares of company stock valued at $429,157. 30.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

SGHT has been the topic of a number of analyst reports. Wall Street Zen raised Sight Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. HC Wainwright assumed coverage on Sight Sciences in a research report on Thursday, October 15th. They set a “buy” rating and a $14.00 target price for the company. UBS Group increased their target price on Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Citigroup raised their price target on Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday, October 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sight Sciences in a research note on Friday, August 7th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.25.

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.